Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia.
about
European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemiaLong-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trIdentification of potent Yes1 kinase inhibitors using a library screening approach.First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib.Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia.A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia.Practical management of patients with chronic myeloid leukemia.Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009.The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phaseAn update on dual Src/Abl inhibitors.Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysisTyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid leukemia.Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg dailyNCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemiaBosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial.Interpretation of cytogenetic and molecular results in patients treated for CML.Moving on up: Second-Line Agents as Initial Treatment for Newly-Diagnosed Patients with Chronic Phase CML.The choice of first-line chronic myelogenous leukemia treatment.The clinical significance of achieving different levels of cytogenetic response in patients with chronic phase chronic myeloid leukemia after failure to front-line therapy: is complete cytogenetic response the only desirable endpoint?Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response?Chronic myeloid leukemia: mechanisms of resistance and treatment.Outcome of treatment of chronic myeloid leukemia with second-generation tyrosine kinase inhibitors after imatinib failureBeyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer.Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies.The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitorsImproved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experienceEUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience.Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy.Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study.Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors.Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction.Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes.Quality control methods for optimal BCR-ABL1 clinical testing in human whole blood samplesImpact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia.How I treat newly diagnosed chronic phase CMLEarly responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalitiesOutcome after failure of second generation tyrosine kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemiaSignificance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors
P2860
Q26749324-7DB8DCCC-6F39-41F6-A57B-3B5E599226CBQ31033077-56BDA38F-DAF1-4392-A45E-8012EE15DDD8Q31119738-D0F785D3-8717-42A0-B9C8-7B62113BB591Q33392977-E8ACF1E6-431D-478C-B00C-AD3E54C3116AQ33398716-2C0F3179-4E0B-47E4-80CB-B7BC2C438EF7Q33401360-EB099BD3-31A2-4F62-8DBE-F0354A8731A2Q33402939-2080CBA0-0B87-4975-B520-4EA6C4EBFD4AQ33849146-CFFDBC22-95CB-4387-8D0F-0329BD81EC0CQ33926114-892A0566-1603-46D9-8C99-50FA2B0EB77EQ34032263-4B735A86-01C1-4E2C-846C-AD6AAE97B298Q34270677-FF68B7B1-7A53-4B92-B9C3-681398014DC3Q34272887-6B708720-5B48-48E9-936A-142FD41A1130Q34272962-D3A4970F-F6B2-4C54-A57B-A8FCC24316A2Q34297594-5ECEBE65-87F7-49ED-B2A8-5012506E4DC6Q34451624-2B05651A-9EF4-4FFA-842F-04752E4C74D9Q34522789-9A7CE517-A5AE-4462-A1DB-8C0A0474FC58Q34763374-A51C50B8-80D3-4C07-8DFF-8FF183A2E9E0Q34765448-745D79F4-411F-45E0-9137-FFB66F97539FQ35117747-07015CF9-8D64-49C0-AA4E-D90E027594D6Q35221071-C7DBAA9C-2C63-41D4-86F8-CC9616BB9EB1Q35548766-0A1514F9-6126-4FBC-96EF-AB5E3FB6BB06Q35565658-C734BA01-105C-4E86-AC85-9E33B6024997Q35595795-AE6EA53F-AC9D-4095-A8D3-EDAF20E0AA66Q35596200-1A64A4B6-6B5F-416A-8685-376B6BD4D0F6Q35653820-44F906B0-AEBA-4D87-9057-21BFFC61AB17Q35794105-0261DD92-AA10-44B9-BF23-D361BAA21E68Q35794115-D4EE34D3-A9B2-4B93-B1BE-6EAADDBF8075Q35849204-3B587C4E-D175-4151-AEEC-DFF865E3AAA3Q35995232-C9B31C56-7608-4314-8DA2-5C6D99F1F2ACQ36094702-087CD7BF-60CB-4FE6-A696-A637121224A3Q36104098-2BC0065F-338D-4FD6-9156-7B7A78348CEFQ36450182-5D008394-53F3-4ACC-90F9-3C6D68B3C1A9Q36624496-FD5B4809-5D10-40E9-8358-BB3F40E8E416Q36734508-EDF894EC-CFD9-4A56-8FC6-2BF55A882514Q36817650-9F2D3651-D2D8-4ABB-8299-2DE5CE921526Q36920407-7168F11F-AB6E-4C2C-B024-0DBDDA938669Q37027767-124354F9-623F-4BC8-A1CE-2B84DD2980E3Q37095355-09F5E035-205F-4B66-BB2B-AC7CA8788D0CQ37117967-00682C63-3CE0-4226-B5D4-C995D15DC78CQ37361209-1CE1995A-F7EB-4FD1-B89D-BC4BAFABBA27
P2860
Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia.
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Results of dasatinib therapy i ...... hase chronic myeloid leukemia.
@ast
Results of dasatinib therapy i ...... hase chronic myeloid leukemia.
@en
type
label
Results of dasatinib therapy i ...... hase chronic myeloid leukemia.
@ast
Results of dasatinib therapy i ...... hase chronic myeloid leukemia.
@en
prefLabel
Results of dasatinib therapy i ...... hase chronic myeloid leukemia.
@ast
Results of dasatinib therapy i ...... hase chronic myeloid leukemia.
@en
P2093
P2860
P50
P356
P1476
Results of dasatinib therapy i ...... hase chronic myeloid leukemia.
@en
P2093
Brenda Walker
Charles Koller
Jianqin Shan
Weiqiang Zhao
P2860
P304
P356
10.1200/JCO.2009.25.4920
P407
P577
2009-12-14T00:00:00Z